Drugs / BI 765883
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06528093 | Oct 2024 → Mar 2025 | pancreatic ductal adenocarcinoma | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765883 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06528093 ↗ |
| Route | Intravenous | “Participants received BI 765883 at doses of 0.4 mg/kg or 1.3 mg/kg, administered intravenously.” NCT06528093 ↗ |